It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lifestyle choices leading to obesity, hypertension and diabetes in mid-life contribute directly to the risk of late-life Alzheimer’s disease (AD). However, in late-life or in late-stage AD conditions, obesity reduces the risk of AD and disease progression. To examine the mechanisms underlying this paradox, TgF344-AD rats were fed a varied high-carbohydrate, high-fat (HCHF) diet to induce obesity from nine months of age representing early stages of AD to twelve months of age in which rats exhibit the full spectrum of AD symptomology. We hypothesized regions primarily composed of gray matter, such as the somatosensory cortex (SSC), would be differentially affected compared to regions primarily composed of white matter, such as the striatum. We found increased myelin and oligodendrocytes in the somatosensory cortex of rats fed the HCHF diet with an absence of neuronal loss. We observed decreased inflammation in the somatosensory cortex despite increased AD pathology. Compared to the somatosensory cortex, the striatum had fewer changes. Overall, our results suggest that the interaction between diet and AD progression affects myelination in a brain region specific manner such that regions with a lower density of white matter are preferentially affected. Our results offer a possible mechanistic explanation for the obesity paradox.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Sunnybrook Research Institute, Biological Sciences, Toronto, Canada (ISNI:0000 0004 0469 1398); University of Toronto, Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
2 Sunnybrook Research Institute, Biological Sciences, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0004 0469 1398)
3 Sunnybrook Research Institute, Biological Sciences, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0004 0469 1398); University of Toronto, Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)